Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of clinical factor changes with immune checkpoint inhibitors in gastrointestinal cancer
jRCT1050220135Recruiting
- Sponsor
- Shiga University of Medical Science
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nivolumab and pembrolizumab in gastric cancer (GC) and esophageal cancer (2 arms), sponsored by Shiga University of Medical Science. Primary endpoints: Progression-free survival and Overall survival. Started Dec 2022; status: recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on jRCT1050220135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050220135.